Search

Your search keyword '"Wit, Ferdinand W N M"' showing total 291 results
Start Over Author "Wit, Ferdinand W N M"
291 results on '"Wit, Ferdinand W N M"'

2. Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort

Author

Jongen, Vita W, Wit, Ferdinand W N M, Boyd, Anders, van Eeden, Arne, Brouwer, Annemarie E, Soetekouw, Robert, El Moussaoui, Rachida, Stalenhoef, Janneke, Sigaloff, Kim C E, Mudrikova, Tatiana, Gisolf, Jet, Burger, David, Wensing, Annemarie M J, and van der Valk, Marc

Abstract

Real-world data showing the long-term effectiveness of long-acting injectable cabotegravir and rilpivirine are scarce. We assessed the effectiveness of cabotegravir and rilpivirine in all individuals who switched to cabotegravir and rilpivirine in the Netherlands.

Published
2025
Full Text
View/download PDF

4. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study

Author

Vasylyev, Marta, primary, Wit, Ferdinand W N M, additional, Jordans, Carlijn C E, additional, Soetekouw, Robin, additional, van Lelyveld, Steven F L, additional, Kootstra, Gert-Jan, additional, Delsing, Corine E, additional, Ammerlaan, Heidi S M, additional, van Kasteren, Marjo E E, additional, Brouwer, Annemarie E, additional, Leyten, Eliane M S, additional, Claassen, Mark A A, additional, Hassing, Robert-Jan, additional, den Hollander, Jan G, additional, van den Berge, Marcel, additional, Roukens, Anna H E, additional, Bierman, Wouter F W, additional, Groeneveld, Paul H P, additional, Lowe, Selwyn H, additional, van Welzen, Berend J, additional, Richel, Olivier, additional, Nellen, Jeannine F, additional, van den Berk, Guido E L, additional, van der Valk, Marc, additional, Rijnders, Bart J A, additional, and Rokx, Casper, additional

Published
2024
Full Text
View/download PDF

5. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Oomen, Patrick G A, Wit, Ferdinand W N M, Brinkman, Kees, Vrouenraets, Saskia M E, Mudrikova, Tania, van Welzen, Berend J, van der Valk, Marc, ATHENA National Observational Cohort Study, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Oomen, Patrick G A, Wit, Ferdinand W N M, Brinkman, Kees, Vrouenraets, Saskia M E, Mudrikova, Tania, van Welzen, Berend J, van der Valk, Marc, and ATHENA National Observational Cohort Study

Published
2024

6. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study

Author

Van der Valk, M., Van Kasteren, M.E.E., Schippers, E.F., Leyten, E.M.S., Kroon, F.P., Den Hollander, J.G., Lowe, S.H., Mulder, J.W., Brinkman, K., Gisolf, E.H., Reiss, P., Zaheri, S., Hillebregt, M., van der Ende, M.E., Howard, Jaime F Borjas, Rokx, Casper, Smit, Colette, Wit, Ferdinand W N M, Pieterman, Elise D, Meijer, Karina, Rijnders, Bart, Bierman, Wouter F W, and Tichelaar, Y I G Vladimir

Published
2019
Full Text
View/download PDF

7. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

Author

Oomen, Patrick G A, Wit, Ferdinand W N M, Brinkman, Kees, Vrouenraets, Saskia M E, Mudrikova, Tania, van Welzen, Berend J, van der Valk, Marc, van Agtmael, M.A., Bomers, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lemkes, B., Nellen, F.J.B., Peters, E.J.G., van der Poll, T., Prins, J.M., Sigaloff, K.C.E., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., Laan, L.M., Pijnappel, F.J.J., Smalhout, S.Y., Spelbrink, M.E., Weijsenfeld, A.M., Back, N.K.T., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Welkers, M.R.A., Wolthers, K.C., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Bree, C., de Munnik, E.S., Phaf, S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., Nellen, J., van Eeden, A., Hoornenborg, E., de Stoppelaar, S., Alers, W., Elsenburg, L.J.M., Nobel, H., Schinkel, C.J., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Pawels-van Rijkevoorsel, M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Mulder, M.A., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van de Ven, E., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Langbein, M., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., van Holten, N., van der Sluis, D., Claas, E.C.J., Wessels, E., den Hollander, J.G., El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., Stoop, A., van Wolfswinkel, M.E., Ackens, R.P., Elasri, M., Houben-Pintaric, K., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., Timmer, C., van Broekhuizen, M.C., Faber, S., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., Stander, B., Cohen Stuart, J.W.T., Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., ter Hofstede, H.J.M., Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Rahamat-Langendoen, J., Ruizendaal, E., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., ter Beest, G., van Bentum, P.H.M., Neijland, Y., Valette, M., Swanink, C.M.A., Klein Velderman, M., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., Griffioen-van Santen, B.M.G., de Kroon, I., Schuurman, R., Verduyn Lunel, F.M., Wensing, A.M.J., van der Valk, M., Zaheri, S., Boyd, A.C., Bezemer, D.O., Jongen, V.W., van Sighem, A.I., Smit, C., Wit, F.W.M.N., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Koster, L.E., Lelivelt, K.J., van de Sande, L., Schoorl, M.J.C., Visser, K.M., van der Vliet, S.T., Paling, F., van den Akker, M., Akpomukai, O.M., Alexander, R., Bakker, Y.M., Bastos Sales, L., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Grolleman, J.M., El Hammoud, I., Khouw, M.R., Lodewijk, C.R.E., Lucas, E.G.A., van Meerveld-Derks, S., Mulder, H.W., Munjishvili, L., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., van Veen, R., van Vliet-Klein Gunnewiek, W.H.G., and Witte, E.C.M.

Abstract

Currently, real-world data on doravirine are scarce. In a national prospective cohort, we assessed the effectiveness and tolerability of switching to doravirine-based antiretroviral therapy (ART) in people with HIV.

Published
2024
Full Text
View/download PDF

8. First-line antiretroviral therapy initiation for newly diagnosed people with HIV in the Netherlands: A retrospective analysis from 2016 to 2020.

Author

Oosterhof, Piter, Wit, Ferdinand W. N. M., van Luin, Matthijs, van der Valk, Marc, Brinkman, Kees, and Burger, David M.

Subjects
*HIV-positive persons, *ANTIRETROVIRAL agents, *HEALTH facilities, *RETROSPECTIVE studies, *MICROSATELLITE repeats, *HIV
Abstract

Introduction: HIV treating physicians in the Netherlands follow the guidelines of the Department of Health and Human Services (DHHS). Most of these recommended initial regimens are single-tablet regimens (STRs), which incur higher costs. By the end of 2017, generic NRTI backbones had become widely available, offering a potentially cheaper multi-tablet regimen. This study aimed to evaluate guideline compliance in people with HIV who started antiretroviral therapy (ART), the uptake of generic multi-tablet regimens (gMTRs), and associated medication costs. Methods: This retrospective cohort study used data from the Dutch HIV Monitoring Foundation to determine the proportion of treatment-naïve people entering care who initiated ART according to the DHHS and type of ART regimens prescribed between January 2016 and December 2020. We analyzed ART prescriptions, both at the national level and per individual HIV treatment centers. We calculated the monthly ART costs based on Dutch medicine prices listed on www.medicijnkosten.nl for each calendar year. Results: In 2016, an integrase inhibitor-containing regimen was initiated in 77.3% which increased to 87.8% in 2020. The compliance rate to DHHS-recommended initial regimens ranged from 82.8% in 2016 to 90.9% in 2020. Most patients received single-tablet regimens, 81.3% in 2016 to 60.3% in 2020. After the introduction the gMTRs showed a steady increase from 17.8% in 2018 to 37.8% in 2020. The cost of the first-line regimen per patient decreased by 22.9% in 2020 compared with 2017. The decrease was larger in centers where treatment-naïve individuals with HIV were preferentially initiated on a gMTR. Conclusions: There was a high compliance to the "DHHS-recommended initial regimens for most people with HIV" in the Netherlands. Most people who initiated ART received STRs, although the percentage of people who started on STRs gradually decreased over time. The use of gMTRs increased over time and was associated with lower medication costs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls.

Author

Verburgh, Myrthe L, Boyd, Anders, Loeff, Maarten F Schim van der, Bakker, Margreet, Wit, Ferdinand W N M, van der Valk, Marc, Grobben, Marloes, Pul, Lisa van, Tejjani, Khadija, Rijswijk, Jacqueline van, Gils, Marit J van, Kootstra, Neeltje A, van der Hoek, Lia, Reiss, Peter, and Study, AGEhIV Cohort

Subjects
COVID-19, SARS-CoV-2, SARS-CoV-2 Omicron variant, HIV infections, PROPORTIONAL hazards models
Abstract

Background Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGEhIV coronavirus disease 2019 substudy participants with well-controlled HIV on antiretroviral therapy and 280 comparable controls, who had received at least the primary vaccination series. Methods From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model. Results The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization. Conclusions People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration. NCT01466582 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus : Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project

Author

Comorbidity in Relations to AIDS (COBRA) Collaboration, Cole, James H., Caan, Matthan W. A., Underwood, Jonathan, De Francesco, Davide, van Zoest, Rosan A., Wit, Ferdinand W. N. M., Mutsaerts, Henk J. M. M., Leech, Rob, Geurtsen, Gert J., Portegies, Peter, Majoie, Charles B. L. M., van der Loeff, Maarten F. Schim, Sabin, Caroline A., Reiss, Peter, Winston, Alan, and Sharp, David J.

Published
2018

12. Gray and White Matter Abnormalities in Treated Human Immunodeficiency Virus Disease and Their Relationship to Cognitive Function

Author

Comorbidity in Relation to AIDS (COBRA) Collaboration, Underwood, Jonathan, Cole, James H., Caan, Matthan, De Francesco, Davide, Leech, Robert, van Zoest, Rosan A., Su, Tanja, Geurtsen, Gert J., Schmand, Ben A., Portegies, Peter, Prins, Maria, Wit, Ferdinand W. N. M., Sabin, Caroline A., Majoie, Charles, Reiss, Peter, Winston, Alan, and Sharp, David J.

Published
2017

14. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV

Author

Verburgh, Myrthe L., primary, van Pul, Lisa, additional, Grobben, Marloes, additional, Boyd, Anders, additional, Wit, Ferdinand W. N. M., additional, van Nuenen, Ad C., additional, van Dort, Karel A., additional, Tejjani, Khadija, additional, van Rijswijk, Jacqueline, additional, Bakker, Margreet, additional, van der Hoek, Lia, additional, Schim van der Loeff, Maarten F., additional, van der Valk, Marc, additional, van Gils, Marit J., additional, Kootstra, Neeltje A., additional, Reiss, Peter, additional, Reiss, P., additional, Wit, F. W. N. M., additional, van der Valk, M., additional, Boyd, A., additional, Verburgh, M. L., additional, van der Wulp, I. A. J., additional, Vanbellinghen, M. C., additional, van Eeden, C. J., additional, Schim van der Loeff, M. F., additional, Koole, J. C. D., additional, del Grande, L., additional, Agard, I., additional, Zaheri, S., additional, Hillebregt, M. M. J., additional, Ruijs, Y. M. C., additional, Benschop, D. P., additional, el Berkaoui, A., additional, Kootstra, N. A., additional, Harskamp-Holwerda, A. M., additional, Maurer, I., additional, Mangas Ruiz, M. M., additional, Boeser-Nunnink, B. D. N., additional, Starozhitskaya, O. S., additional, van der Hoek, L., additional, Bakker, M., additional, van Gils, M. J., additional, Dol, L., additional, Rongen, G., additional, Geerlings, S. E., additional, Goorhuis, A., additional, Hovius, J. W. R., additional, Nellen, F. J. B., additional, Prins, J. M., additional, van der Poll, T., additional, Wiersinga, W. J., additional, van Vugt, M., additional, de Bree, G., additional, Lemkes, B. A., additional, Spoorenberg, V., additional, van Eden, J., additional, Pijnappel, F. J. J., additional, Weijsenfeld, A., additional, Smalhout, S., additional, Hylkema-van den Bout, I. J., additional, Bruins, C., additional, Spelbrink, M. E., additional, Postema, P. G., additional, Bisschop, P. H. L. T., additional, Dekker, E., additional, van der Velde, N., additional, Franssen, R., additional, Willemsen, J. M. R., additional, Vogt, L., additional, Portegies, P., additional, Geurtsen, G. J., additional, Visser, I., additional, Schadé, A., additional, Nieuwkerk, P. T., additional, van Steenwijk, R. P., additional, Jonkers, R. E., additional, Majoie, C. B. L. M., additional, Caan, M. W. A., additional, van den Born, B. J. H., additional, Stroes, E. S. G., additional, and van Oorspronk, S., additional

Published
2023
Full Text
View/download PDF

16. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care

Author

Dutch HIV Adolescents and Young Adults (AYA) Study Group, Weijsenfeld, Annouschka M., Smit, Colette, Cohen, Sophie, Wit, Ferdinand W. N. M., Mutschelknauss, Michelle, van der Knaap, Linda C., van Zonneveld, Laura M., Zomer, Bert J., Nauta, Nike, Patist, Joke C., Kuipers-Jansen, Marien H. J., Smit, Esther P., Blokhuis, Charlotte, and Pajkrt, Dasja

Published
2016
Full Text
View/download PDF

18. Biomarkers of central and peripheral inflammation mediate the association between HIV and depressive symptoms

Author

Mudra Rakshasa-Loots, Arish, Bakewell, Nicholas, Sharp, David J., Gisslén, Magnus, Zetterberg, Henrik, Alagaratnam, Jasmini, Wit, Ferdinand W. N. M., Kootstra, Neeltje A., Winston, Alan, Reiss, Peter, Sabin, Caroline A., and Vera, Jaime H.

Abstract

People living with HIV are at increased risk for depression, though the underlying mechanisms for this are unclear. In the general population, depression is associated with peripheral and central inflammation. Given this, and since HIV infection elicits inflammation, we hypothesised that peripheral and central inflammatory biomarkers would at least partly mediate the association between HIV and depressive symptoms. People living with HIV (n = 125) and without HIV (n = 79) from the COmorBidity in Relation to AIDS (COBRA) cohort were included in this study. Participants living with and without HIV had similar baseline characteristics. All participants living with HIV were on antiretroviral therapy and were virally suppressed. Plasma, CSF, and brain MR spectroscopy (MRS) biomarkers were measured. Using logistic regression models adjusted for sociodemographic factors, we found that participants with HIV were more likely to have Any Depressive Symptoms (Patient Health Questionnaire [PHQ-9] score >4) (odds ratio [95% confidence interval] 3.27 [1.46, 8.09]). We then sequentially adjusted the models for each biomarker separately to determine the mediating role of each biomarker, with a >10% reduction in OR considered as evidence of potential mediation. Of the biomarkers analysed, MIG (−15.0%) and TNF-α (−11.4%) in plasma and MIP1-α (−21.0%) and IL-6 (−18.0%) in CSF mediated the association between HIV and depressive symptoms in this sample. None of the other soluble or neuroimaging biomarkers substantially mediated this association. Our findings suggest that certain biomarkers of central and peripheral inflammation may at least partly mediate the relationship between HIV and depressive symptoms.

Published
2023
Full Text
View/download PDF

19. Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands

Author

van den Hof, Malon, Smit, Colette, van Rossum, Annemarie M. C., Fraaij, Pieter L. A., Wolfs, Tom F. W., Geelen, Sibyl P. M., Scherpbier, Henriette J., Schölvinck, Elisabeth H., van Aerde, Koen, Reiss, Peter, Wit, Ferdinand W. N. M., Pajkrt, Dasja, Pediatrics, Epidemiology and Data Science, APH - Methodology, APH - Societal Participation & Health, ARD - Amsterdam Reproduction and Development, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Amsterdam institute for Infection and Immunity, Global Health, AII - Infectious diseases, and APH - Aging & Later Life

Subjects
SDG 3 - Good Health and Well-being
Abstract

Objectives To provide an overview of the demographics, treatment characteristics and long-term outcomes of children with perinatal HIV-1 infection (PHIV) living in the Netherlands (NL) and to specifically investigate whether outcomes differ by children's adoption status. Design A prospective population-based open cohort including children with PHIV in NL. Methods We included children with PHIV who had entered HIV care in NL since 2007, in view of a sharp increase in the number of adopted children with PHIV since that year. We compared the proportion with virologic suppression and CD4+T-cell count over time between the following groups of children with PHIV: adopted and born outside NL, non-adopted born in NL, and non-adopted born outside NL, using generalized estimating equations and linear mixed effects models, respectively. To account for the variation in cohort inclusion, we analyzed data of children exposed to at least one year of antiretroviral therapy (ART). Results We included 148 children (827.5 person-years of follow-up, 72% adopted, age at start care in NL 2.4 (0.5-5.3)). Under-18 mortality was zero. Over the years, a boosted PI-based regimen was most often prescribed. The use of integrase inhibitors increased since 2015. Nonadopted children born in NL were less likely to achieve virological suppression compared to adopted children (OR 0.66, 95%CI 0.51-0.86, p = 0.001), which disappeared after excluding one child with suspected treatment nonadherence (OR 0.85, 95%CI 0.57-1.25, p = 0.400). CD4+T-cell Z-score trajectories were not significantly different between groups. Conclusions Despite considerable and increasing diversity of the population of children with PHIV in NL, geographical origin and adoption status do not seem to pose important challenges in achieving good immunological and virological outcomes.

Published
2023

20. Long-Term Virological Treatment Outcomes in Adolescents and Young Adults With Perinatally and Non-Perinatally Acquired Human Immunodeficiency Virus

Author

Weijsenfeld, Annouschka M., Smit, Colette, Wit, Ferdinand W. N. M., Mudrikova, Tania, Nellen, Jeannine F. J. B., van der Valk, Marc, Pajkrt, Dasja, Graduate School, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Infectious diseases, ARD - Amsterdam Reproduction and Development, APH - Aging & Later Life, APH - Digital Health, APH - Personalized Medicine, APH - Global Health, and Internal medicine

Subjects
young adults, viral suppression, Infectious Diseases, Oncology, antiretroviral therapy, longitudinal study, HIV
Abstract

Background Long-term viral suppression on antiretroviral therapy (ART) is not established among all people with human immunodeficiency virus (PWH). Young adults (18–24 years) are recognized as a group vulnerable for suboptimal virological treatment outcomes. The aim of this study is to evaluate longitudinal virological treatment outcomes and to identify risk factors for virological failure (VF) among young adults with non-perinatally and perinatally acquired human immunodeficiency virus (HIV) in the Netherlands. Methods We included individuals registered in the national ATHENA observational cohort from 2000 until 2020 who had entered care before the age of 25 years, who had received ART for at least 6 months with at least 2 available HIV ribonucleic acid measurements between the age of 18 and 24 years. We compared VF between age groups 12–17, 18–24, and 25–30 years. A multivariable generalized linear mixed model was used to evaluate risk factors for VF. Analyses were stratified by HIV acquisition mode. Results In total, 1174 non-perinatally PWH and 157 perinatally PWH were included. In 2020, VF rate was 7% in non-perinatally PWH young adults and 19% in perinatally PWH young adults. The adjusted risk for VF was significantly higher in those aged 18–24 compared to 25–30 years in both non-perinatally PWH (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.07–1.50) and perinatally PWH (OR, 2.34; 95% CI, 1.48–3.71). Conclusions Young adulthood is a vulnerable period, with increased risk for VF, especially for perinatally PWH. The probability of VF decreased over time, but less for perinatally PWH compared to non-perinatally PWH.

Published
2022
Full Text
View/download PDF

26. Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV

Author

Verburgh, Myrthe L, Boyd, Anders, Wit, Ferdinand W N M, Schim van der Loeff, Maarten F, van der Valk, Marc, Bakker, Margreet, Kootstra, Neeltje A, van der Hoek, Lia, and Reiss, Peter

Subjects
SARS-CoV-2, viruses, virus diseases, COVID-19, HIV, HIV Infections, Antibodies, Viral, “SARS-CoV-2”, “incidence”, Immunoglobulin A, “COVID-19”, Cohort Studies, “HIV”, AcademicSubjects/MED00290, “serology”, Immunoglobulin G, Major Article, Humans, Nucleocapsid
Abstract

Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups.Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression.The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P = .61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels.HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort.NCT01466582.

Published
2021

27. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Author

Lambert-Niclot, S., George, E. C., Pozniak, A., White, E., Schwimmer, C., Jessen, H., Johnson, M., Dunn, D., Perno, C. F., Clotet, B., Plettenberg, A., Blaxhult, A., Palmisano, L., Wittkop, L., Calvez, V., Marcelin, A. G., Raffi, F., Dedes, Nikos, Chêne, Geneviève, Richert, Laura, Allavena, Clotilde, Raffi, François, Autran, Brigitte, Antinori, Andrea, Bucciardini, Raff aella, Vella, Stefano, Horban, Andrzej, Arribas, Jose, Babiker, Abdel G., Boffito, Marta, Pillay, Deenan, Pozniak, Anton, Franquet, Xavier, Schwarze, Siegfried, Grarup, Jesper, Chêne, Geneviève, Fischer, Aurélie, Richert, Laura, Wallet, Cédrick, Raffi, François, Diallo, Alpha, Molina, Jean-Michel, Saillard, Juliette, Moecklinghoff, Christiane, Stellbrink, Hans-Jürgen, Vella, Stefano, Van Leeuwen, Remko, Gatell, Jose, Sandstrom, Eric, Flepp, Markus, Babiker, Abdel G, Ewings, Fiona, George, Elizabeth C., Hudson, Fleur, Pozniak, Anton, Pearce, Gillian, Quercia, Romina, Rogatto, Felipe, Leavitt, Randi, Nguyen, Bach-Yen, Goebel, Frank, Marcotullio, Simone, Babiker, Abdel G., Ewings, Fiona, George, Elizabeth C., Hudson, Fleur, Kaur, Navrup, Sasieni, Peter, Spencer-Drake, Christina, Peto, Tim, Miller, Veronica, Allavena, Clotilde, Raffi, François, Vella, Stefano, Pozniak, Anton, Arnault, Fabien, Boucherie, Céline, Fischer, Aurélie, Jean, Delphine, Paniego, Observer Virginie, Paraina, Felasoa, Richert, Laura, Rouch, Elodie, Schwimmer, Christine, Soussi, Malika, Taieb, Audrey, Termote, Monique, Touzeau, Guillaume, Wallet, Cédrick, Babiker, Abdel G., Cursley, Adam, Dodds, Wendy, Ewings, Fiona, George, Elizabeth C., Hoppe, Anne, Hudson, Fleur, Kummeling, Ischa, Pacciarini, Filippo, Paton, Nick, Russell, Charlotte, Taylor, Kay, Ward, Denise, Aagaard, Bitten, Eid, Marius, Gey, Daniela, Jensen, Birgitte Gram, Grarup, Jesper, Jakobsen, Marie-Louise, Jansson, Per O., Jensen, Karoline, Joensen, Zillah Maria, Larsen, Ellen Moseholm, Pahl, Christiane, Pearson, Mary, Nielsen, Birgit Riis, Reilev, Søren Stentoft, Christ, Ilse, Lathouwers, Desiree, Manting, Corry, Van Leeuwen, Remko, Diallo, Alpha, Mendy, Bienvenu Yves, Metro, Annie, Saillard, Juliette, Couffin-Cadiergues, Sandrine, Knellwolf, Anne-Laure, Palmisiano, Lucia, Aznar, Esther, Barea, Cristina, Cotarelo, Manuel, Esteban, Herminia, Girbau, Iciar, Moyano, Beatriz, Ramirez, Miriam, Saiz, Carmen, Sanchez, Isabel, Yllescas, Maria, Binelli, Andrea, Colasanti, Valentina, Massella, Maurizio, Palmisiano, Lucia, Anagnostou, Olga, Gioukari, Vicky, Touloumi, Giota, Schmied, Brigitte, Rieger, Armin, Vetter, Norbert, De Wit, Stephane, Florence, Eric, Vandekerckhove, Linos, Gerstoft, Jan, Mathiesen, Lars, Katlama, Christine, Cabie, Andre, Cheret, Antoine, Dupon, Michel, Ghosn, Jade, Girard, Pierre-Marie, Goujard, Cécile, Lévy, Yves, Molina, Jean-Michel, Morlat, Philippe, Neau, Didier, Obadia, Martine, Perre, Philippe, Piroth, Lionel, Reynes, Jacques, Tattevin, Pierre, Raffi, François, Ragnaud, Jean Marie, Weiss, Laurence, Yazdan, Yazdanpanah, Yeni, Patrick, Zucman, David, Behrens, Georg, Esser, Stefan, Fätkenheuer, Gerd, Hoffmann, Christian, Jessen, Heiko, Rockstroh, Jürgen, Schmidt, Reinhold, Stephan, Christoph, Unger, Stefan, Hatzakis, Angelos, Daikos, George L., Papadopoulos, Antonios, Skoutelis, Athamasios, Banhegyi, Denes, Mallon, Paddy, Mulcahy, Fiona, Antinori, Andrea, Andreoni, Massimo, Bonora, Stefano, Castelli, Francesco, Monforte, Antonella DʼArminio, Di Perri, Giovanni, Galli, Massimo, Lazzarin, Adriano, Mazzotta, Francesco, Carlo, Torti, Vullo, Vincenzo, Prins, Jan, Richter, Clemens, Verhagen, Dominique, Van Eeden, Arne, Horban, Andrzej, Doroana, Manuela, Antunes, Francisco, Maltez, Fernando, Sarmento-Castro, Rui, Garcia, Juan Gonzalez, Aldeguer, José López, Clotet, Bonaventura, Domingo, Pere, Gatell, Jose M., Knobel, Hernando, Marquez, Manuel, Miralles, Martin Pilar, Portilla, Joaquin, Soriano, Vicente, Tellez, Maria-Jesus, Thalme, Anders, Blaxhult, Anders, Gisslen, Magnus, Winston, Alan, Fox, Julie, Gompels, Mark, Herieka, Elbushra, Johnson, Margaret, Leen, Clifford, Pozniak, Anton, Teague, Alastair, Williams, Ian, Boyd, Mark Alastair, Grarup, Jesper, Jansson, Per O., Møller, Nina Friis, Larsen, Ellen Frøsig Moseholm, Morlat, Philippe, Piroth, Lionel, Le Moing, Vincent, Wit, Ferdinand W. N. M., Kowalska, Justyna, Berenguer, Juan, Moreno, Santiago, Müller, Nicolas J., Török, Estée, Post, Frank, Angus, Brian, Calvez, Vincent, Boucher, Charles, Collins, Simon, Dunn, David, Lambert, Sidonie, Marcelin, Anne-Geneviève, Perno, Carlo Federico, Pillay, Deenan, White, Ellen, Boffito, Marta, Ammassari, Adriana, Antinori, Andrea, Stoehr, Wolgang, Autran, Brigitte, Schmidt, Reinhold Ernst, Odermarsky, Michal, Smith, Colette, Thiébaut, Rodolphe, Arribas, Jose, De La Serna, Jose Ignacio Bernardino, Castagna, Antonella, De Wit, Stephane, Franquet, Xavier, Furrer, Hans-Jackob, Katlama, Christine, Mocroft, Amanda, Reiss, Peter, Bucciardini, Raffaella, Dedes, Nikos, Fragola, Vincenzo, George, Elizabeth C., Lauriola, Marco, Murri, Rita, Nieuwkerk, Pythia, Spire, Bruno, Volny-Anne, Alain, West, Brian, Amieva, Hélène, Antinori, Andrea, Llibre Codina, Josep Maria, Richert, Laura, Stoehr, Wolgang, Winston, Alan, Castelli, Francesco, Braggion, Marco, and Focà, Emanuele

Published
2016
Full Text
View/download PDF

28. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated hiv rna and dna levels as compared with therapy based on protease inhibitors

Author

Pasternak, Alexander O., Vroom, Jelmer, Kootstra, Neeltje A., Wit, Ferdinand W. N. M., de Bruin, Marijn, de Francesco, Davide, Bakker, Margreet, Sabin, Caroline A., Winston, Alan, Prins, Jan M., Reiss, Peter, Berkhout, Ben, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Experimental Immunology, APH - Aging & Later Life, Infectious diseases, and Global Health

Subjects
virus diseases
Abstract

BACKGROUND: It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress HIV replication. Here, we report the results of two crosssectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). METHODS: CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n=100, n=124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically-measured adherence to ART. RESULTS: In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho=0.70 and rho=0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj=0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj=0.048 and padj=0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals CONCLUSIONS: All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.

Published
2021

31. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV

Author

Verburgh, Myrthe L, primary, Boyd, Anders, additional, Wit, Ferdinand W N M, additional, Schim van der Loeff, Maarten F, additional, van der Valk, Marc, additional, Bakker, Margreet, additional, Kootstra, Neeltje A, additional, van der Hoek, Lia, additional, and Reiss, Peter, additional

Published
2021
Full Text
View/download PDF

36. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

Author

Byonanebye, Dathan M., Polizzotto, Mark N., Begovac, Josip, Grabmeier-Pfistershammer, Katharina, Abela, Irene, Castagna, Antonella, De Wit, Stephane, Mussini, Cristina, Vehreschild, Joerg J., Monforte, Antonella d'A, Wit, Ferdinand W. N. M., Pradier, Christian, Chkhartishvili, Nikoloz, Sonnerborg, Anders, Hoy, Jennifer, Lundgren, Jens, Neesgaard, Bastian, Bansi-matharu, Loveleen, Greenberg, Lauren, Llibre, Josep M., Vannappagari, Vani, Gallant, Joel, Necsoi, Coca, Cichon, Piotr, Reiss, Peter, Aho, Inka, Tsertsvadze, Tengiz, Mennozzi, Marianna, Rauch, Andri, Muccini, Camilla, Law, Matthew, Mocroft, Amanda, Ryom, Lene, Petoumenos, Kathy, Byonanebye, Dathan M., Polizzotto, Mark N., Begovac, Josip, Grabmeier-Pfistershammer, Katharina, Abela, Irene, Castagna, Antonella, De Wit, Stephane, Mussini, Cristina, Vehreschild, Joerg J., Monforte, Antonella d'A, Wit, Ferdinand W. N. M., Pradier, Christian, Chkhartishvili, Nikoloz, Sonnerborg, Anders, Hoy, Jennifer, Lundgren, Jens, Neesgaard, Bastian, Bansi-matharu, Loveleen, Greenberg, Lauren, Llibre, Josep M., Vannappagari, Vani, Gallant, Joel, Necsoi, Coca, Cichon, Piotr, Reiss, Peter, Aho, Inka, Tsertsvadze, Tengiz, Mennozzi, Marianna, Rauch, Andri, Muccini, Camilla, Law, Matthew, Mocroft, Amanda, Ryom, Lene, and Petoumenos, Kathy

Abstract

Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6-3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0-201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59-0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15-1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00-1.43) and raltegravir (1.24; CI 1.02-1.51), but lower with rilpivirine (0.77; CI 0.63-0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.

Published
2021

37. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy

Author

Leth, Frank van, Huisamen, Casper B., Wit, Ferdinand W. N. M., Badaro, Roberto, Lange, Joep M. A., Hall, David B., Vandercam, Bernard, Wet, Joss de, and Montaner, Julio S. G.

Subjects
Nevirapine -- Research, RNA -- Research, Health, Efavirenz (Medication) -- Research
Abstract

An interim analysis based on the data from the first 400 patients to assess possible differences in plasma HIV-1RNA (pVL) decline between the treatment groups is presented. A similar rate of initial decline of pVL for nevirapine (NVP), efavirenz (EFV), and NVP + EFV after adjusting for baseline pVL and region is shown.

Published
2005

39. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV.

Author

Verburgh, Myrthe L, Boyd, Anders, Wit, Ferdinand W N M, Loeff, Maarten F Schim van der, van der Valk, Marc, Bakker, Margreet, Kootstra, Neeltje A, van der Hoek, Lia, and Reiss, Peter

Abstract

Background Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)–positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. Methods Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. Results The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P  = .61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. Conclusions HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. Clinical Trial Registration NCT01466582. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Longitudinal virological outcomes and factors associated with virological failure in behaviorally HIV-infected young adults on combination antiretroviral treatment in the Netherlands, 2000 to 2015

Author

Weijsenfeld, Annouschka M., Blokhuis, Charlotte, Stuiver, Martijn M., Wit, Ferdinand W. N. M., Pajkrt, Dasja, Singh, Sarman, Amsterdam Reproduction & Development (AR&D), General Paediatrics, APH - Health Behaviors & Chronic Diseases, APH - Quality of Care, Master Evidence Based Practice, Global Health, AII - Infectious diseases, APH - Aging & Later Life, and Paediatric Infectious Diseases / Rheumatology / Immunology

Subjects
Male, young adults, Cart, Pediatrics, medicine.medical_specialty, Blood transfusion, Adolescent, Sexual Behavior, medicine.medical_treatment, Observational Study, HIV Infections, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Risk Factors, medicine, Humans, Longitudinal Studies, Treatment Failure, 030212 general & internal medicine, Young adult, Netherlands, virological failure, business.industry, Racial Groups, HIV, General Medicine, Viral Load, Virological failure, Confidence interval, CD4 Lymphocyte Count, Anti-Retroviral Agents, 030220 oncology & carcinogenesis, HIV-1, combination antiretroviral therapy, Drug Therapy, Combination, Female, Observational study, business, Viral load, Research Article
Abstract

Achieving and maintaining viral suppression in young adults (18–24 years) living with HIV is challenging. Overall HIV viral suppression rates are lower in young as compared to older adults. Longitudinal data provide valuable insight on dynamics of viral suppression and variables of potential influence on HIV virological failure (VF), but is scarce in young adults living with HIV on combination antiretroviral therapy (cART). We evaluated longitudinal virological outcomes of behaviorally young adults (18–24 years) living with HIV in the Netherlands over a period of 15 years. We analyzed data from the Dutch national HIV database of 816 young adults living with HIV on cART in the Netherlands from 2000 to 2015. VF was defined as 2 consecutive detectable plasma HIV-1 viral load (VL) measurements > 200 copies/ml. Generalized linear mixed model analyses were used to assess HIV VF over time and identify risk factors associated with VF. VF during the study follow-up occurred at least once in 26% of cases. The probability of experiencing VF decreased over the study period per calendar year (OR 0.78, 95% confidence interval [CI];0.72; 0.85). Factors significantly associated with VF were being infected through heterosexual contact (OR 5.20, CI 1.39;19.38) and originating from Latin America or the Caribbean (OR 6.59, CI 2.08;20.92). Smaller, yet significant risk factors for VF were being infected through a blood transfusion or a needle accident (OR9.93, CI 1.34;73.84, and having started with cART with a nadir CD4 count >500 cells/μl (OR 11.36, CI 2.03;63.48). In our large cohort of young adults, the risk of VF has diminished over 15 years. Specific subgroups were identified to be at risk for suboptimal treatment.

Published
2019

43. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

Author

Neesgaard, Bastian, Mocroft, Amanda, Greenberg, Lauren, Larsen, Jakob Friis, Wandeler, Gilles, Zangerle, Robert, Gunthard, Huldrych, Smith, Colette, De Wit, Stephane, Mussini, Cristina, Castagna, Antonella, Monforte, Antonella D'Arminio, Vehreschild, Joerg Janne, Wasmuth, Jan-Christian, Pradier, Christian, Chkhartishvili, Nikoloz, Wit, Ferdinand W. N. M., Law, Matthew, Sonnerborg, Anders, Bruguera, Andreau, Stephan, Christoph, Vannappagari, Vani, Haubrich, Richard, Kirk, Ole, Podlekareva, Daria, Kowalska, Justyna, Raben, Dorthe, Rockstroh, Juergen, Peters, Lars, Parades, Roger, Grabmeier-Pfistershammer, Katharina, Scherrer, Alexandra, Johnson, Margaret, Necsoi, Coca, Borghi, Vanni, Muccini, Camilla, Tserstvadze, Tengiz, Petoumenos, Kathy, Volny-Anne, Alain, Lundgren, Jens, Ryom, Lene, Neesgaard, Bastian, Mocroft, Amanda, Greenberg, Lauren, Larsen, Jakob Friis, Wandeler, Gilles, Zangerle, Robert, Gunthard, Huldrych, Smith, Colette, De Wit, Stephane, Mussini, Cristina, Castagna, Antonella, Monforte, Antonella D'Arminio, Vehreschild, Joerg Janne, Wasmuth, Jan-Christian, Pradier, Christian, Chkhartishvili, Nikoloz, Wit, Ferdinand W. N. M., Law, Matthew, Sonnerborg, Anders, Bruguera, Andreau, Stephan, Christoph, Vannappagari, Vani, Haubrich, Richard, Kirk, Ole, Podlekareva, Daria, Kowalska, Justyna, Raben, Dorthe, Rockstroh, Juergen, Peters, Lars, Parades, Roger, Grabmeier-Pfistershammer, Katharina, Scherrer, Alexandra, Johnson, Margaret, Necsoi, Coca, Borghi, Vanni, Muccini, Camilla, Tserstvadze, Tengiz, Petoumenos, Kathy, Volny-Anne, Alain, Lundgren, Jens, and Ryom, Lene

Abstract

Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naive, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/mu L (438-830). Malignancies (n= 361) and cardiovascular disease (n= 168) were the predominant reported clinical events. Conclusion: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

Published
2020

44. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies

Author

Trickey, Adam, May, Margaret T., Gill, M. John, Grabar, Sophie, Vehreschild, Janne, Wit, Ferdinand W. N. M., Bonnet, Fabrice, Cavassini, Matthias, Abgrall, Sophie, Berenguer, Juan, Wyen, Christoph, Reiss, Peter, Grabmeier-Pfistershammer, Katharina, Guest, Jodie L., Shepherd, Leah, Teira, Ramon, Monforte, Antonella d'Arminio, del Amo, Julia, Justice, Amy, Costagliola, Dominique, Sterne, Jonathan A. C., Trickey, Adam, May, Margaret T., Gill, M. John, Grabar, Sophie, Vehreschild, Janne, Wit, Ferdinand W. N. M., Bonnet, Fabrice, Cavassini, Matthias, Abgrall, Sophie, Berenguer, Juan, Wyen, Christoph, Reiss, Peter, Grabmeier-Pfistershammer, Katharina, Guest, Jodie L., Shepherd, Leah, Teira, Ramon, Monforte, Antonella d'Arminio, del Amo, Julia, Justice, Amy, Costagliola, Dominique, and Sterne, Jonathan A. C.

Abstract

People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and several non-ADMs (NADMs). Information is lacking on survival outcomes and cause-specific mortality after cancer diagnosis among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North American HIV cohorts starting antiretroviral therapy (ART) 1996-2015, aged >= 16 years, and subsequently diagnosed with cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause-specific mortality rates (MR) after diagnosis of specific cancers and compared 5-year survival with the UK and France general populations. Among 83,856 PLHIV there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847 (55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were higher for diagnoses between 1996 and 2005 versus 2006-2015: ADMs 102 (95% CI 92-113) per 1,000 years versus 88 (78-100), viral NADMs 134 (106-169) versus 111 (93-133) and nonviral NADMs 264 (232-300) versus 226 (206-248). Estimated 5-year survival for PLHIV diagnosed with liver (29% [19-39%]), lung (18% [13-23%]) and cervical (75% [63-84%]) cancer was similar to general populations. Survival after Hodgkin's lymphoma diagnosis was lower in PLHIV (75% [67-81%]). Among ART-treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS.

Published
2020

49. The ADAM study continued: maintenance therapy after 50 weeks of induction therapy

Author

Reijers, Monique H. E., Weverling, Gerrit Jan, Jurriaans, Suzanne, Roos, Marijke T. L., Wit, Ferdinand W. N. M., Weigel, Hugo M., Kate, Reinier W. Ten, Mulder, Jan Willem, Richter, Clemens, Hofstede, Hadewich J. M. Ter, Sprenger, Herman, Hoetelmans, Richard M. W., Schuitemaker, Hanneke, and Lange, Joep M. A.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results